NEO TECT KIT
LOE ApproachingPeptidetechnetium tc-99m depreotide
NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEO TECT KIT is a technetium Tc-99m labeled radiopharmaceutical diagnostic agent containing depreotide, a somatostatin analog. It is used for scintigraphic imaging to detect neuroendocrine tumors and other somatostatin receptor-positive lesions. The drug localizes to somatostatin receptors on tumor cells, enabling visualization during nuclear medicine imaging procedures.
LOE Approaching
As a legacy diagnostic radiopharmaceutical approaching loss of exclusivity with 30% competitive pressure, the brand team is likely small and focused on defensive market retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEO TECT offers limited career advancement opportunity given its mature, declining lifecycle and minimal hiring activity. This role would suit professionals seeking stable, defensive market management rather than high-growth product launches.
Diagnostic Medical RepresentativeProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.